These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21292860)

  • 1. Diagnostic utility of boronic acid inhibition with different cephalosporins against Escherichia coli producing AmpC β-lactamases.
    Upadhyay S; Sen MR; Bhattacharjee A
    J Med Microbiol; 2011 May; 60(Pt 5):691-3. PubMed ID: 21292860
    [No Abstract]   [Full Text] [Related]  

  • 2. Detection of plasmid-mediated AmpC in Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis.
    Tan TY; Ng SY; Teo L; Koh Y; Teok CH
    J Clin Pathol; 2008 May; 61(5):642-4. PubMed ID: 18057079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.
    Doi Y; Wachino J; Ishiguro M; Kurokawa H; Yamane K; Shibata N; Shibayama K; Yokoyama K; Kato H; Yagi T; Arakawa Y
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2652-8. PubMed ID: 15215122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis.
    Coudron PE
    J Clin Microbiol; 2005 Aug; 43(8):4163-7. PubMed ID: 16081966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
    Bethel CR; Hujer AM; Helfand MS; Bonomo RA
    FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.
    Mammeri H; Nazic H; Naas T; Poirel L; Léotard S; Nordmann P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4050-3. PubMed ID: 15388478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aza-boronic acids as non-beta-lactam inhibitors of AmpC-beta-lactamase.
    Buzzoni V; Blazquez J; Ferrari S; Calò S; Venturelli A; Costi MP
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3979-83. PubMed ID: 15225711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disc methods for detecting AmpC {beta}-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Brenwald NP; Jevons G; Andrews J; Ang L; Fraise AP
    J Antimicrob Chemother; 2005 Sep; 56(3):600-1. PubMed ID: 16087656
    [No Abstract]   [Full Text] [Related]  

  • 9. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC.
    Haldorsen B; Aasnaes B; Dahl KH; Hanssen AM; Simonsen GS; Walsh TR; Sundsfjord A; Lundblad EW
    J Antimicrob Chemother; 2008 Oct; 62(4):694-702. PubMed ID: 18583329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression levels of chromosomal AmpC β-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins.
    Paltansing S; Kraakman M; van Boxtel R; Kors I; Wessels E; Goessens W; Tommassen J; Bernards A
    Microb Drug Resist; 2015 Feb; 21(1):7-16. PubMed ID: 25188329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of extended-spectrum beta-lactamases by using boronic acid as an AmpC beta-lactamase inhibitor in clinical isolates of Klebsiella spp. and Escherichia coli.
    Song W; Bae IK; Lee YN; Lee CH; Lee SH; Jeong SH
    J Clin Microbiol; 2007 Apr; 45(4):1180-4. PubMed ID: 17301276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay of efflux, impermeability, and AmpC activity contributes to cefuroxime resistance in clinical, non-ESBL-producing isolates of Escherichia coli.
    Källman O; Giske CG; Samuelsen Ø; Wretlind B; Kalin M; Olsson-Liljequist B
    Microb Drug Resist; 2009 Jun; 15(2):91-5. PubMed ID: 19432520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of extended-spectrum-AmpC-expressing Escherichia coli isolates in Belgian hospitals.
    Bogaerts P; Rodriguez-Villalobos H; Laurent C; Deplano A; Struelens MJ; Glupczynski Y
    J Antimicrob Chemother; 2009 May; 63(5):1073-5. PubMed ID: 19240070
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel.
    Goren MG; Chmelnitsky I; Carmeli Y; Navon-Venezia S
    J Antimicrob Chemother; 2011 Mar; 66(3):672-3. PubMed ID: 21177669
    [No Abstract]   [Full Text] [Related]  

  • 15. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
    Weston GS; Blázquez J; Baquero F; Shoichet BK
    J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway.
    Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A
    Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AmpC beta-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131.
    Oteo J; Cercenado E; Cuevas O; Bautista V; Delgado-Iribarren A; Orden B; Pérez-Vázquez M; García-Cobos S; Campos J
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):270-6. PubMed ID: 20462723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum beta-lactamases in Escherichia coli.
    Netzel TC; Jindani I; Hanson N; Turner BM; Smith L; Rand KH
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):345-8. PubMed ID: 17379469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital.
    Mammeri H; Eb F; Berkani A; Nordmann P
    J Antimicrob Chemother; 2008 Mar; 61(3):498-503. PubMed ID: 18250231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CMY-2-type plasmid-mediated AmpC ß-lactamases emerging in Tucumán, Argentina].
    Jure MA; Presti C; Cudmani NM; Grellet LM; López C; Musa EH; Aulet OC; Nieto C; Saavedra L; de Castillo MC
    Rev Argent Microbiol; 2011; 43(1):24-7. PubMed ID: 21491062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.